Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $6.34. Cyclacel Pharmaceuticals shares last traded at $6.27, with a volume of 47,140 shares changing hands.
A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 11th. Oppenheimer assumed coverage on Cyclacel Pharmaceuticals in a research note on Thursday, April 29th. They issued an “outperform” rating and a $17.00 price target on the stock.
The stock has a 50 day moving average of $6.90. The company has a market capitalization of $57.90 million, a price-to-earnings ratio of -2.17 and a beta of 1.22.
A number of institutional investors have recently made changes to their positions in the business. Virtu Financial LLC increased its stake in shares of Cyclacel Pharmaceuticals by 27.3% during the first quarter. Virtu Financial LLC now owns 13,108 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 2,815 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Cyclacel Pharmaceuticals during the first quarter valued at approximately $169,000. Point72 Asset Management L.P. purchased a new position in shares of Cyclacel Pharmaceuticals during the first quarter valued at approximately $1,635,000. Verition Fund Management LLC purchased a new position in shares of Cyclacel Pharmaceuticals during the first quarter valued at approximately $830,000. Finally, Citadel Advisors LLC purchased a new position in shares of Cyclacel Pharmaceuticals during the first quarter valued at approximately $2,090,000. 44.31% of the stock is currently owned by institutional investors and hedge funds.
Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Further Reading: Diversification in Investing
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.